Table 3.

Effect of IL-18 administration on donor T-cell responses in primary and secondary MLR

cpmIFN-γ, pg/mLIL-4, pg/mL
Primary MLR    
 Syngeneic 247 ± 39 38 ± 21 UD 
 Allogeneic + control 37 358 ± 1596 4473 ± 296 UD 
 Allogeneic + IL-18 32 649 ± 4771 3362 ± 958 UD 
Seconday MLR    
 Syngeneic 979 ± 254 675 ± 342 13 ± 6 
 Allogeneic + control 76 988 ± 9752 16 786 ± 1041 23 ± 7 
 Allogeneic + IL-18 48 676 ± 6453* 9863 ± 474* 94 ± 12* 
cpmIFN-γ, pg/mLIL-4, pg/mL
Primary MLR    
 Syngeneic 247 ± 39 38 ± 21 UD 
 Allogeneic + control 37 358 ± 1596 4473 ± 296 UD 
 Allogeneic + IL-18 32 649 ± 4771 3362 ± 958 UD 
Seconday MLR    
 Syngeneic 979 ± 254 675 ± 342 13 ± 6 
 Allogeneic + control 76 988 ± 9752 16 786 ± 1041 23 ± 7 
 Allogeneic + IL-18 48 676 ± 6453* 9863 ± 474* 94 ± 12* 

BALB/c mice were injected with IL-18 or diluent (control) for 10 days, as in “Materials and methods.” Splenic T (CD3+) cells were harvested on day 11 and cultured in primary MLR (n = 3/group) with irradiated B6 splenocytes for 96 hours. Culture supernatants were collected for cytokine measurement and proliferation was determined by pulsing with 3H-thymidine (1 μCi/well [0.037 MBq/well]) for an additional 16 hours. Secondary MLR responder T cells from bulk primary MLRs were then removed and restimulated with irradiated B6 peritoneal cells. After 48 hours of culture, supernatants were collected for cytokine measurement, and proliferation was determined by pulsing with3H-thymidine (1 μCi/well [0.037 MBq/well]) for an additional 20 hours. *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal